Craft
Idorsia

Idorsia

Projects in R&D Pipeline

12

FY, 2019

Revenue

CHF35.3 M

FY, 2021

Market Capitalization

CHF2.3 B

2022-09-19

Idorsia Summary

Company summary

Overview
Idorsia (formerly Actelion) is a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. It targets a number of different diseases, such as Fabry disease, insomnia, resistant hypertension, cerebral vasospasm, epilepsy, nasal polyposis, systemic lupus erythematosus, and others. The company focuses on multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.
Type
Public
Founded
2017
HQ
Allschwil, CH | view all locations
Website
https://www.idorsia.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Mathieu Simon, Chairman, Executive Member

    • Martine Clozel

      Martine Clozel, Executive Vice President, Chief Scientific Officer

      • André C. Muller

        André C. Muller, Executive Vice President, Chief Financial Officer

      • Simon Jose

        Simon Jose, Executive Vice President, Chief Commercial Officer

      Operating MetricsView all

      Projects in R&D Pipeline

      12
      20.0%

      FY, 2019

      Workstations

      550

      FY, 2019

      Complex Systems Completed

      31

      FY, 2018

      LocationsView all

      5 locations detected

      • Allschwil, Basel-Landschaft HQ

        Switzerland

        91 Hegenheimermattweg

      • NJ

        United States

      • Shanghai, Shanghai

        China

      • Lörrach, BW

        Germany

        Marie-Curie-Straße 8

      • Chiyoda City, Tōkyō-to

        Japan

      Idorsia Financials

      Summary financials

      Revenue (Q2, 2022)
      CHF17.1M
      Gross profit (Q2, 2022)
      CHF15.8M
      Net income (Q2, 2022)
      (CHF221.6M)
      Cash (Q2, 2022)
      CHF233.0M
      EBIT (Q2, 2022)
      (CHF212.1M)
      Enterprise value
      $3.3B

      Footer menu